Theranexus implements a new equity line of an amount of up to €8.4 million in total over 12 months


Lyon, 18 January 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological
diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial
cells, presents an update on its activities and announces the strengthening of its financial visibility
for the medium term.